The AlphaLISA® immunoassay kit for human GAD67 enables the quantitative determination of human glutamate decarboxylase 67 (hGAD67) in serum and cell culture supernatants using a homogeneous AlphaLISA assay (no wash steps). The assay shows less than 5% cross reactivity with mouse GAD67. Cross-reactivity with other species has not tested.
For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Glutamic acid decarboxylase 67 (GAD67) is an enzyme that catalyzes more than 90% of γ-amino butyric acid by glutamate decarboxylation. GAD67 is expressed in the brain and must be active at all times for normal cellular functioning. Dysregulation of GAD67 in the hippocampal stratum oriens layer correlates to the pathophysiology of schizophrenia, bipolar disorders, and Parkinson’s. This enzyme, as well as GAD65, is a target of autoantibodies in humans who develop type 1 diabetes later in their life. This AlphaLISA detection kit allows for the detection of GAD67 levels in serum, plasma, and cell culture supernatants.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
|Assay Target Class||Protein|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Central Nervous System|
|Unit Size||5,000 assay points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.